PharmaShots Interview: Guardant Health’s Kathryn Lang Shares Insight on the Data of Guardant360 Liquid Biopsy Test for the Treatment of Advanced Non-Small Cell Lung Cancer

In an interview with PharmaShots, Kathryn Lang, Vice President, Outcomes & Evidence at Guardant Health shared her views on the data from the VALUE study of Guardant360 liquid biopsy test for NSCLCShots:The VALUE study evaluates the clinical outcomes & utility of liquid biopsy vs tissue biopsy testing in patients with NSCLC across six Canadian centersIn an initial diagnosis, patients treated…